Del Labs sales and earnings
This article was originally published in The Tan Sheet
Net sales jump 12.8% to $332.7 mil. in 2001, driven in part by "double-digit sales increases" in Orajel line, strong gains in cosmetics segment, firm announces Feb. 21. Also, Dermarest "continues as the number one brand of OTC psoriasis treatments," Uniondale, N.Y.-based Del notes. Net earnings more than doubled to $9.8 mil. for the year. Fourth quarter sales were up 16.4% to $85.7 mil., while earnings soared 149.6% to $2.8 mil...
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.